ArticleScientific reports2018
Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Organoids: From Bench to Bedside Applications.MedComm · 2026Review
- Conditionally Reprogrammed Cells Preserve Cellular Diversity and Permit Genetic Manipulation: Implications for Cancer Heterogeneity and Tissue Regeneration.Serican journal of medicine · 2026Article
- Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Review
- Modeling respiratory tract diseases for clinical translation employing conditionally reprogrammed cells.Cell insight · 2024Review
- Characterization of a Diverse Set of Conditionally Reprogrammed Head and Neck Cancer Cell Cultures.The Laryngoscope · 2024Article
- Review
- Insights into the characteristics of primary radioresistant cervical cancer using single-cell transcriptomics.Human cell · 2023Article
- Article
- Patient-derived spheroids and patient-derived organoids simulate evolutions of lung cancer.Heliyon · 2023Article
- Establishment of a diverse head and neck squamous cancer cell bank using conditional reprogramming culture methods.Journal of medical virology · 2023Article
- Article
- Review
- Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models.Neuro-oncology · 2021Article
- Rapid screening for individualized chemotherapy optimization of colorectal cancer: A novel conditional reprogramming technology-based functional diagnostic assay.Translational oncology · 2021Article
- Application Research of Individualized Conditional Reprogramming System to Guide Treatment of Gastric Cancer.Frontiers in oncology · 2021Article
- Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy.Frontiers in oncology · 2021Review
- Conditional cell reprogramming for modeling host-virus interactions and human viral diseases.Journal of medical virology · 2020Review
- Personalized drug testing in a patient with non-small-cell lung cancer using cultured cancer cells from pleural effusion.The Journal of international medical research · 2020Article
- Conditional reprogramming: next generation cell culture.Acta pharmaceutica Sinica. B · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Preclinical in vitro models provide an essential tool to study cancer cell biology as well as aid in translational research, including drug target identification and drug discovery efforts. For any model to be clinically relevant, it needs to recapitulate the biology and cell heterogeneity of the primary tumor. We recently developed and described a conditional reprogramming (CR) cell technology that addresses many of these needs and avoids the deficiencies of most current cancer cell lines, which are usually clonal in origin. Here, we used the CR cell method to generate a collection of patient-derived cell cultures from non-small cell lung cancers (NSCLC). Whole exome sequencing and copy number variations are used for the first time to address the capability of CR cells to keep their tumor-derived heterogeneity. Our results indicated that these primary cultures largely maintained the molecular characteristics of the original tumors. Using a mutant-allele tumor heterogeneity (MATH) score, we showed that CR cells are able to keep and maintain most of the intra-tumoral heterogeneity, suggesting oligoclonality of these cultures. CR cultures therefore represent a pre-clinical lung cancer model for future basic and translational studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.